---
document_datetime: 2025-09-17 14:08:24
document_pages: 5
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/viagra-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: viagra-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 7.6596713
conversion_datetime: 2025-12-23 06:37:35.046277
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Viagra

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency' s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessmenthistory'section.Forthe completeproduct lifecycleprocedures,you mayneedtoalsorefertoEPAR-Proceduralstepstakenandscientific informationafterauthorisation(archive).

| Applicationnumber   | Scope                                 | Opinion/ Notification 1 issued on   | Commission Decision IssuedÂ²/ amended on   | Product Information affected3   | Summary   |
|---------------------|---------------------------------------|-------------------------------------|-------------------------------------------|---------------------------------|-----------|
| Article 61(3) /     | Notificationacc.Article61(3)-Accepted | 15/09/2025                          |                                           |                                 |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions areissuedfor all otherprocedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

2 A Commission decision(CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annexII, labelling,package leaflet).The CDisissuedwithintwomonths of the opinionforvariationsfallingunderthescope ofArticle23.1a(a)ofRegulation(EU)No.712/2012,orwithinoneyearforotherprocedures.

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/N/0000296269                      | Update of the package leaflet with revised contactdetailsoflocalrepresentative and deletion of 'United Kingdom (Northern Ireland)' from the list of local representatives in line with the QRD template v10.4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |            |     |
|---------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IB / EMA/VR/0000242792 | This was an application for a group of variations. B.I.a.1Changeinthemanufacturerofa startingmaterial/reagent/intermediateused in themanufacturingprocessoftheactive substance orchange in themanufacturer (including where relevant quality control testing sites)of the active substance,where no Ph. Eur. Certificate of Suitability is part of the approved dossier-B.I.a.1.f Changes to quality control testing arrangements for the active substance-replacement or addition of a sitewherebatchcontrol/testingtakes place - Accepted B.I.a.1 Change in the manufacturer of a startingmaterial/reagent/intermediateused in themanufacturingprocessoftheactive substance orchangeinthemanufacturer (including where relevant quality control | 28/03/2025 | N/A |
|                                       | testing sites)of the active substance,where no Ph. Eur. Certificate of Suitability is part of the approved dossier-B.I.a.1.aThe                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |            |     |

<div style=\"page-break-after: always\"></div>

|                                       | proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer- Accepted B.1.b.2 Change in test procedure for active substanceorstarting material/reagent/intermediateusedinthe manufacturing process of the active substance-B.I.b.2.e Other changes to a test procedure (including replacement or addition)forthe active substance or a startingmaterial/intermediate-Accepted                                                                                 |            |     |      |
|---------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------|
| Variation type IB / EMA/VR/0000247514 | B.II.f.1.bExtensionoftheshelflifeofthe finished product - B.II.f.1.b.1 As packaged for sale (supported by real time data) - Accepted                                                                                                                                                                                                                                                                                                                                                                    | 04/03/2025 |     | SmPC |
| Variation type IA / EMA/VR/0000236674 | A. ADMINISTRATIVE CHANGES - A.4 Change in thename and/or address of:a manufacturer (including where relevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, startingmaterial,reagentorintermediate used inthemanufacture of the active substance(wherespecifiedin thetechnical dossier)where noPh.Eur.Certificate of Suitability is part of the approved dossier; or a manufacturer of a novel excipient (where specified in the technical dossier)-Accepted | 18/12/2024 | N/A |      |

<div style=\"page-break-after: always\"></div>

|                                       | A. ADMINISTRATIVE CHANGES -A.4 Change in thename and/or address of:a manufacturer(includingwhererelevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, starting material, reagent or intermediate usedinthemanufactureoftheactive substance(where specified in thetechnical dossier) where no Ph. Eur. Certificate of Suitabilityispart of the approveddossier;or a manufacturer of a novel excipient (where specified in the technical dossier)- Accepted B.III.1.a European Pharmacopoeial CertificateofSuitability totherelevantPh. Eur. Monograph - B.1II.1.a.2 Updated certificate from an already approved manufacturer-Accepted   |            |     |
|---------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IB / EMA/VR/0000183094 | C.1.11 Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the risk management plan-C.I.11.a Implementation of wording agreed by the competent authority- Accepted To update the RMP following assessment as part of EMEA/H/C/PSUSA/00002699/202112 andEMEA/H/C/000202/X/0115.                                                                                                                                                                                                                                                                                                                                                  | 28/08/2024 | N/A |

<div style=\"page-break-after: always\"></div>

| Article 61(3) / EMA/N/0000224658   | - Notification acc. Article 61(3) - Accepted Update of the package leaflet with revised contactdetailsoflocalrepresentatives. Additionally, the MAH took the opportunity tointroduce a minor linguistic amendment to the Italian translation.   | 21/08/2024   | 13/01/2025   | PL   |
|------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------|